261 related articles for article (PubMed ID: 3301391)
1. The development of virus-free labile blood derivatives--a review.
Prince AM; Horowitz B; Horowitz MS; Zang E
Eur J Epidemiol; 1987 Jun; 3(2):103-18. PubMed ID: 3301391
[TBL] [Abstract][Full Text] [Related]
2. Specific inactivation of viruses which can potentially contaminate blood products.
Horowitz B
Dev Biol Stand; 1991; 75():43-52. PubMed ID: 1794631
[TBL] [Abstract][Full Text] [Related]
3. Laboratory and preclinical evaluation of the virus safety of coagulation factor concentrates.
Horowitz B; Prince AM
Dev Biol Stand; 1987; 67():291-302. PubMed ID: 3609483
[TBL] [Abstract][Full Text] [Related]
4. Inactivation of viruses found with plasma proteins.
Horowitz B
Biotechnology; 1991; 19():417-30. PubMed ID: 1786476
[TBL] [Abstract][Full Text] [Related]
5. Viral safety of solvent-detergent treated blood products.
Horowitz B; Prince AM; Horowitz MS; Watklevicz C
Dev Biol Stand; 1993; 81():147-61. PubMed ID: 8174797
[TBL] [Abstract][Full Text] [Related]
6. Clinical evaluation of viral safety of coagulation factor VIII and IX concentrates.
Mannucci PM
Vox Sang; 1993; 64(4):197-203. PubMed ID: 8517048
[TBL] [Abstract][Full Text] [Related]
7. Transfusion-transmitted disease.
Lee CA
Baillieres Clin Haematol; 1996 Jun; 9(2):369-94. PubMed ID: 8800511
[TBL] [Abstract][Full Text] [Related]
8. [Virus safety of fresh frozen plasma].
Sugg U
Beitr Infusionsther; 1989; 24():56-9. PubMed ID: 2481549
[TBL] [Abstract][Full Text] [Related]
9. Safety aspects in the manufacturing of plasma-derived coagulation factor concentrates.
Burnouf T
Biologicals; 1992 Jun; 20(2):91-100. PubMed ID: 1389114
[TBL] [Abstract][Full Text] [Related]
10. Virus safety of human blood, plasma, and derived products.
Guertler L
Thromb Res; 2002 Oct; 107 Suppl 1():S39-45. PubMed ID: 12379292
[TBL] [Abstract][Full Text] [Related]
11. Strategies for viral inactivation.
Horowitz B; Ben-Hur E
Curr Opin Hematol; 1995 Nov; 2(6):484-92. PubMed ID: 9372040
[TBL] [Abstract][Full Text] [Related]
12. Viral safety of clotting factor concentrates.
Fricke WA; Lamb MA
Semin Thromb Hemost; 1993; 19(1):54-61. PubMed ID: 8456324
[TBL] [Abstract][Full Text] [Related]
13. Blood protein derivative viral safety: observations and analysis.
Horowitz B
Yale J Biol Med; 1990; 63(5):361-9. PubMed ID: 1963504
[TBL] [Abstract][Full Text] [Related]
14. Transfusion-transmitted infection in hemophilia in developing countries.
Yee TT; Lee CA
Semin Thromb Hemost; 2005 Nov; 31(5):527-37. PubMed ID: 16276461
[TBL] [Abstract][Full Text] [Related]
15. Viral safety of plasma-derived factor VIII and IX concentrates.
Ludlam CA
Blood Coagul Fibrinolysis; 1997 Aug; 8 Suppl 1():S19-23. PubMed ID: 9351532
[TBL] [Abstract][Full Text] [Related]
16. Virus safety of prothrombin complex concentrates and factor IX concentrates.
Seitz R; Dodt J
Thromb Res; 1999 Aug; 95(4 Suppl 1):S19-23. PubMed ID: 10499905
[TBL] [Abstract][Full Text] [Related]
17. Viral safety of solvent/detergent-treated blood products.
Horowitz B; Prince AM; Hamman J; Watklevicz C
Blood Coagul Fibrinolysis; 1994 Dec; 5 Suppl 3():S21-8; discussion S29-S30. PubMed ID: 7749045
[TBL] [Abstract][Full Text] [Related]
18. Efforts in minimizing risk of viral transmission through viral inactivation.
Horowitz B; Ben-Hur E
Ann Med; 2000 Oct; 32(7):475-84. PubMed ID: 11087168
[TBL] [Abstract][Full Text] [Related]
19. Inactivation of viruses, bacteria, protozoa, and leukocytes in platelet concentrates.
Corash L
Vox Sang; 1998; 74 Suppl 2():173-6. PubMed ID: 9704443
[TBL] [Abstract][Full Text] [Related]
20. Virus inactivation of fresh plasma.
Mohr H
Vox Sang; 1998; 74 Suppl 2():171-2. PubMed ID: 9704442
[No Abstract] [Full Text] [Related]
[Next] [New Search]
